Taysha Gene Therapies, Inc.(TSHA)

$4.37▲0.06 (1.39%)

Taysha Gene Therapies, Inc.(TSHA)

NASDAQ

$4.37▲0.06 (1.39%)

Overview Intelligence Chart Fundamentals Key Metrics Earnings Growth Analysts Financials Insiders Institutional

Analyst Sentiment

Analysts lean bullish — 75% recommend buying.

Consensus Rating

Buy

16 analysts·Moderate coverage

75%

Rating Distribution

Strong Buy

00%

Buy

1275%

Hold

425%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 156% higher.

Bear Case

$8.00

+83%

Consensus

$11.17

+156%

Bull Case

$13.00

+197%

Price Range16 analysts

Low

Consensus

High

$8.00

$13.00

Current Target

Current Price

$4.37

Upside to Target

$6.80

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+3723.16%

EPS—

FY2028

Rev+40.67%

EPS—

FY2029

Rev+141.98%

EPS—

Earnings Surprises

Recent Analyst Actions

Jan 6, 2026Raymond James

Raymond James on Taysha Gene Therapies (TSHA): 'Continued Regulatory Progress For TSHA-102; Remain Strong Buy Rated'

Target:$13.00

+146.9%from $5.26

Jan 5, 2026Wells Fargo

Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo

Target:$11.00

+109.5%from $5.25

Dec 4, 2025Goldman Sachs

Taysha Gene Therapies rated Buy versus Early-Stage at Goldman Sachs

Target:$11.00

+145.0%from $4.49

Dec 4, 2025UBS

Goldman Sachs Upgrades Taysha Gene Therapies (TSHA) to Buy

Target:$11.00

+145.0%from $4.49

Nov 14, 2025Cantor Fitzgerald

Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)

Target:$13.00

+220.6%from $4.05

Nov 5, 2025JMP Securities

Taysha Gene Therapies price target raised to $8 from $6 at Citizens JMP

Target:$8.00

+87.4%from $4.27

Oct 2, 2025Robert W. Baird

Taysha Gene Therapies price target raised to $12 from $7 at Baird

Target:$12.00

+151.8%from $4.76

Oct 2, 2025Needham

Needham ups Taysha target on 'derisking' TSHA-102 news

Target:$10.00

+109.9%from $4.76

Aug 14, 2024BMO Capital

BMO Capital Reiterates Outperform Rating on Taysha Gene Therapies (TSHA)

Target:$5.00

+116.5%from $2.31

Jul 1, 2024Piper Sandler

Taysha Gene Therapies (TSHA) PT Lowered to $7 at Piper Sandler

Target:$7.00

+212.5%from $2.24

May 14, 2024Jefferies

Jefferies Assumes Taysha Gene Therapies (TSHA) at Buy

Target:$8.00

+233.3%from $2.40

Apr 9, 2024Raymond James

Piper Sandler Starts Taysha Gene Therapies (TSHA) at Overweight, 'Innovative Gene Therapy Story'

Target:$9.00

+235.8%from $2.68

Feb 1, 2023Jefferies

Jefferies Downgrades Taysha Gene Therapies to Hold, Lowers Price Target to $1.5

Target:$1.50

-8.5%from $1.64

Oct 19, 2021Morgan Stanley

Taysha Gene Therapies assumed with an Overweight at Morgan Stanley

Target:$39.00

+121.2%from $17.63

May 19, 2021Cantor Fitzgerald

Taysha Gene Therapies initiated with an Overweight at Cantor Fitzgerald

Target:$44.00

+102.0%from $21.78

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance